Summary:
Pharvaris’ pill for hereditary angioedema (HAE) showed promising results in a Phase 3 trial, with a median time to symptom relief of 1.28 hours, significantly faster than a placebo. The company plans to seek FDA approval in the first half of 2026, with an extended release formulation also in development. This drug would join a growing market of HAE treatments, including the recently approved oral drug Ekterly.
Access impact:
If approved, deucrictibant would provide a new treatment option for HAE patients, potentially offering faster relief compared to existing treatments. However, the market for HAE treatments is becoming increasingly competitive, with multiple options already available and more in development. The success of deucrictibant may depend on its ability to differentiate itself from other treatments and attract patients and prescribers.
Top-3 domain lens.
Cost-Effectiveness:
The success of deucrictibant in providing faster symptom relief may make it a cost-effective option for HAE patients, potentially reducing the need for more expensive treatments or hospitalizations. However, more evidence is needed to compare its cost-effectiveness to other HAE treatments.
Evidence Quality and Robustness The Phase 3 trial for deucrictibant showed promising results, with a median time to symptom relief of 1.28 hours and a median time to complete resolution of symptoms of 11.95 hours. However, more evidence will be needed to fully assess its effectiveness and safety, as well as its potential for long-term use.
Budget Impact and Resources:
If reimbursed, deucrictibant would add another option to the growing market for HAE treatments, potentially increasing costs for patients, payers, and healthcare systems. The success of the drug may depend on its ability to demonstrate value and cost-effectiveness compared to other treatments.
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Pharvaris #Deucrictibant
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list
Source: https://www.biopharmadive.com/news/pharvaris-pill-succeeds-in-late-stage-trial-for-rare-swelling-disorder/806890/
In the past we have published our analysts notes on both the HAE on-demand attacks and the HAE prophylaxis (the next indication to be approved).
Here is our take on this very difficult and crowded disease area! https://mararating.com/report/deucrictibant-for-on-demand-treatment-of-hae-attacks-as-of-september-2025/ AND we also have our research on the HAE prophylaxis (next indication) here: https://mararating.com/report/deucrictibant-for-prophylaxis-for-hereditary-angioedema-as-of-june-2025/